LUNCH WORKSHOP: Leveraging Novel Methodologies to Address Key Challenges in Drug Discovery and Development
| Wednesday, December 10, 2025 |
| 1:00 PM - 2:00 PM |
| Hall E1 |
|
Sponsored By:
BioVit
|
Overview
Delivered by BioIVT
Details
Drug discovery and development often present complex questions that require innovative approaches to resolve. Staying abreast of the latest methodologies can significantly accelerate the development process. This presentation will highlight cutting-edge technologies available at BioIVT that support late-stage drug discovery and early development.
Cytokines (small signaling proteins secreted by immune and other cell types) play a pivotal role in regulating inflammation, immunity, and intercellular communication. In the context of hypertension, both pro-inflammatory and anti-inflammatory cytokines influence blood pressure regulation and vascular health. BioIVT’s INTELLIFLEX™ platform enables rapid and multiplexed monitoring of key cytokines, including IL-4, IL-6, IL-10, IL-13, IL-17, IL-18, IL-1β, TGF-β, TNF-α, and others.
Drug-induced liver injury (DILI) remains a major cause of drug withdrawal. The C-DILI™ assay integrates multiple toxicity mechanisms, including direct toxicity, metabolic and transport inhibition/induction, and FXR antagonism) to provide a comprehensive prediction of cholestatic hepatotoxicity.
Accurate prediction of in vivo metabolism is essential for successful drug development. The HEPATOPAC™ platform supports extended hepatocyte culture for up to four weeks, enabling the identification and quantification of slowly formed metabolites. This system also allows for siRNA-mediated knockdown of specific metabolic enzymes and transporters, facilitating mechanistic insights into their in vivo roles.
Finally, we will discuss recent advances in incorporating physiological protein concentrations into in vitro studies, which have shown promise in improving the accuracy of in vivo predictions.
Speaker
Dr Kenneth Brouwer, PhD, RPh
Global Research Liason
BioIVT
Leveraging Novel Methodologies to Address Key Challenges in Drug Discovery and Development
Biography
Kenneth Brouwer is Vice President, ADME Tox Research at BioIVT. A pharmacologist by training, Dr. Brouwer has led in vitro ADME programs at GSK and at PPD. He later led development of B-CLEAR technology, a method to quantitate hepato-biliary excretion. He was a founder of Qualyst Transporter Solutions, where he expanded applications of B-CLEAR technology and developed assays that integrate uptake, efflux, and regulatory function of cells. In 2017, BioIVT acquired Qualyst, and Dr. Brouwer now helps biopharmaceutical clients design and implement in vitro ADME research programs to achieve their drug R&D and regulatory submission objectives.
